A5057357453- Retinal Diseases and Treatments
- Retinal Imaging and Analysis
- Retinal and Optic Conditions
- Glaucoma and retinal disorders
- Ocular Diseases and Behçet’s Syndrome
- Retinal Development and Disorders
- Retinal and Macular Surgery
- Hemoglobinopathies and Related Disorders
- Intraocular Surgery and Lenses
- Cerebral Venous Sinus Thrombosis
- Drug-Induced Ocular Toxicity
- Systemic Lupus Erythematosus Research
- Dermatological and Skeletal Disorders
- Chronic Lymphocytic Leukemia Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Ocular Infections and Treatments
- Acute Ischemic Stroke Management
- Connexins and lens biology
- Sarcoidosis and Beryllium Toxicity Research
- MicroRNA in disease regulation
- Ophthalmology and Eye Disorders
- Salivary Gland Disorders and Functions
- Fetal and Pediatric Neurological Disorders
- Vascular Malformations Diagnosis and Treatment
- Corneal surgery and disorders
Université Sorbonne Paris Nord
2015-2024
Hôpital Avicenne
2015-2024
Assistance Publique – Hôpitaux de Paris
2015-2024
Institut de la Vision
2011-2019
Sorbonne Université
2011-2019
Novartis (Switzerland)
2015-2018
Centre National de la Recherche Scientifique
2011-2018
Laboratoire de Recherche sur la Croissance Cellulaire, la Réparation et la Régénération Tissulaires
2018
Allergan (Ireland)
2018
Bayer (United States)
2018
Neovascular age-related macular degeneration (nAMD) and diabetic edema (DME) patients treated with intravitreally injected anti-vascular endothelial growth factor (anti-VEGF) monotherapies achieve lower vision improvements compared in clinical trials. This qualitative research study aimed to better understand the real-world anti-VEGF treatment experience from nAMD DME patients', caregivers', retina specialists' perspectives.One-time, semi-structured, individual interviews were conducted...
To assess the effect of serous retinal detachment (SRD) on functional and anatomical outcomes in ranibizumab-treated patients with diabetic macular edema (DME).All consecutive SRD were included this retrospective study. For each patient SRD, a without same baseline best-corrected visual acuity (BCVA) was randomly for adjustment their BCVA. All group 1 (G1) those G2. The primary endpoint mean change BCVA between month 12 (M12). Secondary endpoints central thickness (CRT) M12, injection...
Abstract Purpose To report the effectiveness of intravitreal aflibercept (IVT-AFL) treatment for diabetic macular edema (DME) in French clinical practice. Methods APOLLON (NCT02924311) was a prospective, observational cohort study patients with DME. Effectiveness evaluated by change from baseline best-corrected visual acuity (BCVA) at 12 months treatment-naïve (i.e., had not received any anti-vascular endothelial growth factor [anti-VEGF] agent, laser, or steroid IVT-AFL start) and...
Abstract Background Macular edema (ME) results from hyperpermeability of retinal vessels, leading to chronic extravasation plasma components into the retina and hence potentially severe visual acuity loss. Current standard care consists in using intravitreal injections (IVI), which a significant medical economic burden. During diabetic retinopathy (DR) or vein occlusion (RVO), it has recently been shown that focal vascular anomalies (capillary macro-aneurysms, also termed TelCaps) for...
Assess variability in central retinal thickness (CRT) on long-term visual acuity patients with diabetic macular edema (DME) receiving dexamethasone intravitreal (DEX) implant.
Purpose . To assess real-life efficacy of ranibizumab and treatment compliance patients with vision loss secondary to diabetic macular edema (DME). Methods A retrospective study was conducted in DME treated ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) central retinal thickness (CRT) by SD-OCT. All received a loading dose 3 monthly injections followed retreatments on an as-needed basis. The primary endpoint the change VA at M12. Patient follow-up correlation...
To estimate the need for bilateral intravitreal anti-VEGF injections in patients treated neovascular age-related macular degeneration (nAMD), diabetic edema (DME), retinal vein occlusion, choroidal neovascularization (CNV) high myopia, and other causes of CNV.All consecutive with injection over a 1-month period were included prospective multicenter survey. The reason involvement fellow eye pathology requiring treatment recorded. A time interval between longer than 1 month, within period,...
Dystrophin-Dp71 being a key membrane cytoskeletal protein, expressed mainly in Müller cells that provide mechanical link at the cell by direct binding to actin and transmembrane protein complex. Its absence has been related blood-retinal barrier (BRB) permeability through delocalization down-regulation of AQP4 Kir4.1 channels (1). We have previously shown adeno-associated virus (AAV) variant, ShH10, transduces Dp71-null mouse retina efficiently specifically (2,3). Here, we use ShH10 restore...
The aim of this study was to assess the efficacy and safety ranibizumab in patients with diabetic macular edema (DME).We conducted a retrospective analysis consecutive vision loss due DME who were treated ranibizumab. All received loading dose 3 monthly injections followed by re-treatments on an as-needed basis. primary endpoint change best-corrected visual acuity (BCVA) at 12 months. Secondary endpoints central retinal thickness (CRT) number intravitreal (IVI) months.One hundred six eyes 78...
Understanding retinal vascular development is crucial because many diseases such as diabetic retinopathy (in adults) or of prematurity children) are among the leading causes blindness. Given localization protein Dp71 around vessels in adult mice and its role maintaining homeostasis, aim this study was to determine if involved astrocyte regulation. An experimental mouse retinas conducted. Using a dual immunolabeling with antibodies anti-GFAP for astrocytes on sections isolated astrocytes, it...
Purpose: We determined if the ellipsoid zone (EZ) disruption pattern could be predictive of geographic atrophy (GA) at 1 year in dry age-related macular degeneration (AMD). Methods: A retrospective study was done eyes patients with AMD and GA from July to November 2013. Eyes previous choroidal neovascularization were excluded. Based on spectral domain optical coherence tomography (SD-OCT), assessed each timepoint, using a sub-RPE slab derived Cirrus Advanced RPE Analysis software...
Purpose . To assess short-term functional and anatomical outcomes of refractory diabetic macular edema (DME) following a switch from ranibizumab or dexamethasone to aflibercept. Methods We included retrospectively eyes with persistent DME after at least 3 and/or one implant intravitreal injections (IVI). The primary endpoint was the mean change in visual acuity (VA) month 6 (M6) switching. Results Twenty-five were included. Before switching aflibercept, 23 received median 9.5 ranibizumab,...
To report a case of bilateral panuveitis with multifocal choroiditis associated systemic sarcoidosis unmasked by pembrolizumab.A 68-years old woman history metastatic melanoma treated pembrolizumab consulted for blurred vision. The ophthalmologic examination revealed anterior uveitis cells in the chamber and granulomatous keratic precipitates, vitreous confirmed indocyanine green angiography. workup pulmonary biopsy.Pembrolizumab is an immune checkpoint inhibitor therapy used treatment...
Abstract Ischemic microangiopathy was clearly identified in sickle cell disease (SCD) using fluorescein angiography. A prospective observational clinical study conducted to assess the foveal avascular zone (FAZ) area and explore perifoveal microvasculature changes superficial (SCP) deep (DCP) capillary plexus optical coherence tomography angiography (OCTA) compare two genotypes—HbS/HbS (HbSS) HbS/HbC (HbSC)-to control. All consecutive patients with electrophoretic confirmation of SCD were...
COVID-19 pneumonia can be severe, with an unpredictable evolution and high mortality prevalence in older patients. The diagnosis is usually performed by RT-PCR or CT chest scan. Lung ultrasonography (LUS) has been proposed as alternative method to monitor patients pneumonia. To assess the diagnostic performance of LUS, we LUS using a portable device adapting protocol already used Acute Respiratory Syndrome. We score obtained index created for compared lung scan predict oxygen requirements....
Introduction: Understanding patient perspectives of treatment may improve adherence and outcomes. This study explored real-world experiences with anti-vascular endothelial growth factor (anti-VEGF) for diabetic macular edema (DME) neovascular age-related degeneration (nAMD). Methods: multinational, non-interventional, quantitative, cross-sectional, observational survey assessed barriers/burden, patient-reported visual functioning, satisfaction in DME nAMD patients the United States, Kingdom,...
<b><i>Background:</i></b> To report the use of En-face optical coherence tomography (OCT) in a patient treated with docetaxel and tamoxifen for breast cancer detection macular edema (ME) without evidence leakage on fluorescein angiography (FA). <b><i>Case Presentation:</i></b> A 52-year-old woman presented bilateral visual loss 2 months. FA showed no significant while spectral-domain OCT scans both eyes foveolar parafoveolar cystic spaces...
Purpose: To report the very long-term visual prognosis of choroidal neovascularization complicating angioid streaks in antivascular endothelial growth factor era. Methods: Retrospective monocentric study aimed at analyzing patients' demographics, features, streak–associated conditions, and previous current therapies for neovascularization. The main outcome measures were quantitative measurement central retinal pigment epithelial atrophy enlargement by comparing ratio pixels involved on...
AURIGA is the largest real-world study to date evaluate intravitreal aflibercept (IVT-AFL) in treatment of diabetic macular edema (DME) or secondary retinal vein occlusion routine clinical practice. The 24-month outcomes DME cohort from across 11 participating countries are reported here. (NCT03161912) was a prospective observational study. enrolled eligible patients with for whom decision treat IVT-AFL had previously been made by attending physician. Patients were treated up 24 months at...
AURIGA is the largest real-world study to date evaluate intravitreal aflibercept (IVT-AFL) treatment of diabetic macular edema or secondary retinal vein occlusion (RVO) in routine clinical practice. Here, we report 24-month outcomes RVO cohort from France, Germany, Italy, and Taiwan. (NCT03161912) was a prospective observational study. Eligible patients with were enrolled for whom decision treat IVT-AFL had already been made by attending physician. Patients treated up 24 months at physician...